Financialnewsmedia.com News Commentary
‘According to the (Brightfield”s) projections, there would be increases in just about every sector that sells CBD — from dispensaries to smoke shops to medical companies. But perhaps the biggest push, according to Gomez, would be from big-box retailers and national chains who have been eager to get in on the lifestyle craze but have felt stifled by the (older )regulations (that have been replaced by the passage of The 2018 Farm Bill.’
The Yield Growth Corp. (BOSS) (BOSQF) BREAKING NEWS: Yield Growth Corp is pleased to announced that its e-commerce platform will now sell its Urban Juve cannabis Sativa hemp root oil-based products in the United States thanks to the adoption of the 2017 U.S. Farm Bill.
Urban Juve products are now available for sale in the U.S. via the site www.urbanjuve.com. In addition, the company has plans to sell its products through U.S. retailers such as pharmacies, naturopaths, clinics, salons, spas, wellness and beauty stores.
‘U.S. distribution is a cornerstone of our sales strategy for all our brands. Already we have a deal in place to sell our THC and CBD infused products through a 400 retail distribution network in Oregon, and now we have launched U.S. e-commerce sales for our Urban Juve products,’ says Yield Growth CEO Penny Green, ‘Our next step is to set up sales agents in California to access the world”s largest cannabis market.’ Read this and more news for The Yield Growth Corp. at: https://www.financialnewsmedia.com/news-boss
Correction content to follow from a release issue earlier:
Harvest One Cannabis Inc. (TSX-V: HVT.V) (OTCQX: HRVOF) recently announced that its wholly-owned medical subsidiary Satipharm Ltd. (‘Satipharm’) has launched European sales of its recently reformulated CBD capsules, now available online at www.satipharm.com. The first product to market is the Satipharm 10mg CBD Gelpell® capsule that provides superior bioavailability and quality. Bricks and mortar distribution of the 10mg CBD Gelpell® capsules will follow with major retailers throughout the United Kingdom and European Union, with Canadian distribution to follow.
‘We are delighted with the launch of Satipharm”s new website and eCommerce platform, making our clinically proven CBD Gelpell® capsules available to consumers across Europe,’ said Jonathan Hartshorn, President of Satipharm. ‘With our focus on consumer education, GMP certified products, and superior bioavailability, we feel strongly that consumers will adopt Satipharm”s CBD Gelpell® capsules as the product of choice for CBD delivery in the marketplace.’
Harvest One is a global cannabis company that develops and provides innovative lifestyle and wellness products to consumers and patients in regulated markets around the world. The Company”s range of lifestyle solutions is designed to enhance quality of life. Shareholders have significant exposure to the entire cannabis value chain through three wholly-owned subsidiaries: United Greeneries, a Licensed Producer; Satipharm (medical and nutraceutical); and Dream Water Global (consumer), and a minority interest in Burb Cannabis (retail operations). For more information, please visit www.harvestone.com.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM”s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty nine hundred dollars for news coverage of the current press releases issued by The Yield Growth Corp. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains ‘forward-looking statements’ within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. ‘Forward-looking statements’ describe future expectations, plans, results, or strategies and are generally preceded by words such as ‘may’, ‘future’, ‘plan’ or ‘planned’, ‘will’ or ‘should’, ‘expected,’ ‘anticipates’, ‘draft’, ‘eventually’ or ‘projected’. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company”s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact email: email@example.com – +1(561)325-8757
PALM BEACH, Florida, Feb. 7, 2019 /PRNewswire/ — In the horse race to revenues, it seems that CBD infused products market may outpace the cannabis market, with the passage of the 2018 Farm Bill kicking it ahead across the finish line! A report from a cannabis industry analyst, as reported in The Rolling Stone magazine, says: ‘For years, experts have predicted that if the cannabis industry expands at its current rate, the American market will reach $20 billion by 2020. But it turns out that one market is spinning off into a mega-industry of its own: according to a new estimate from cannabis industry analysts the Brightfield Group, the hemp-CBD market alone could hit $22 billion by 2022.’ In fact the Rolling Stone sub-headline sums it up the reason why: ‘Looking forward to relaxed hemp regulations, a new analysis estimates that the CBD market could explode — and outpace marijuana.’. Previously, CBD products have been available mostly in head shops, with a few doctors recommending it for various maladies. But in 2017 and 2018, the products spread to natural food stores, beauty aisles, cafés and doctors offices. So far the industry is on track to hit $591 million in 2018, and thanks to a number of factors — including, surprisingly, Senate Majority Leader Mitch McConnell — that could increase 40 times in the next four years.’ Active companies in the markets this week include The Yield Growth Corp. (BOSS) (BOSQF), Harvest One Cannabis Inc. (TSX-V: HVT.V) (OTCQX: HRVOF).